Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Rob White

- PMLiVE

The evolving biosimilars market

Safety and efficacy doubts remain a challenge

- PMLiVE

Pharma must ‘create new social contract’

New task force established in UK to assess public’s view of the value and risk of medicines

- PMLiVE

Nothing but a shell game

Is health insurance a rigged game?

- PMLiVE

J&J starts to feel biosimilar competition bite

Secondquarter Remicade sales outside the US dropped 26%

- PMLiVE

Making savings from European drugs budgets

National programmes of cuts are the order of the day

Friend or foe?

Payer relationship might have unintended consequences

Novartis day

Novartis heart drug may see novel pricing plan

Swiss firm looking to risk share with payers based on clinical outcomes

- PMLiVE

Opdivo approved via UK’s early drug access scheme

Bristol-Myers Squibb’s immunotherapy the first lung cancer drug approved by EAMS

- PMLiVE

The importance of real-world data to the pharma industry

It is a crucial time to for pharma and other stakeholders to demonstrate medicines' value

- PMLiVE

The blame game

In the 'healthcare spending crisis' it’s important to look beyond sensationalist headlines

- PMLiVE

Overcoming quantitative pricing limitations

Choosing an accurate price for a product without a therapeutic equivalent can feel like a lead in the dark

- PMLiVE

Patients ‘sceptical’ about biosimilars, says EULAR

Concerns for safety of drugs for arthritis and other musculoskeletal diseases

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links